Diagnosis and management of pertussis

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 4, 2005, Pages 509-515

  Tozzi, Alberto E ^a   Pastore Celentano, Lucia ^b   Ciofi Degli Atti, Marta Luisa ^b   Salmaso, Stefania ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; DEXBROMPHENIRAMINE; DIPHENHYDRAMINE; ERYTHROMYCIN; IPRATROPIUM BROMIDE; PSEUDOEPHEDRINE; SALBUTAMOL; TERFENADINE; THEOPHYLLINE; WARFARIN;

BORDETELLA PERTUSSIS; CIRCULATION; CLINICAL FEATURE; COUGHING; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; IMMUNITY; NAUSEA; PERTUSSIS; POLYMERASE CHAIN REACTION; PROPHYLAXIS; REVIEW; RISK FACTOR; SIDE EFFECT; STANDARDIZATION; VACCINATION; VOMITING;

EID: 14044275676     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1040766     Document Type: Review

References (75)

1. Pertussis vaccines. Wkly Epidemiol Rec 1999;74:137-44.
2. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B; Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001;32:1691-7.
3. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003;290:2968-75.
4. Skowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002;185:1448-53.
5. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003;22:22-7.
6. Tozzi AE, Pastore Celentano L, Paramatti D, Lana S. EUVAC-NET pertussis surveillance. Final report. EUVAC.NET; 2004. Available: www.ssi.dk/euvac (click on "Pertussis report" at left; accessed 2005 Jan 13).
7. Miller E, Gay NJ. Epidemiological determinants of pertussis. Dev Biol Stand 1997;89:15-23.
8. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002;2:744-50.
9. Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis 2000;19:77-88.
10. Locht C. Molecular aspects of Bordetella pertussis pathogenesis. Int Microbiol 1999;2:137-44.
11. Tozzi AE, Ravà L, Ciofi degli Atti ML, Salmaso S; Progetto Pertosse Working Group. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of age. Pediatrics 2003;112:1069-75.
12. Preziosi MP, Halloran ME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003;37:772-9.
13. Wang J, Yang Y, Li J, Mertsola J, Arvilommi H, Shen X, et al. Infantile pertussis rediscovered in China. Emerg Infect Dis 2002;8:859-60.
14. Hoppe JE. Neonatal pertussis. Pediatr Infect Dis J 2000;19:244-7.
15. De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville Fradet M, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174-9.
16. Yaari E, Yafe-Zimernam Y, Schwartz SB, Slater PE, Shvartzman P, Andoren N, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 1999;115:1254-8.
17. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997;100(6):E10.
18. Ivanoff B, Robertson SE. Pertussis: a worldwide problem. Dev Biol Stand 1997;89:3-13.
19. Pertussis - United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002;51(4):73-6
20. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992;14:708-19.
21. Halperin SA, Wang EE, Law B, Mills E, Morris R, Dery P, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis 1999;28:1238-43.
22. Stojanov S, Liese J, Belohradsky BH. Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection 2000;28:106-10.
23. Pelosi JW, Schulte JM. Use of birth certificates and surveillance data to characterize reported pertussis among Texas infants and young children, 1995 to 2000. South Med J 2003;96:1231-7.
24. Pertussis - United States, January 1992-June 1995. MMWR Morb Mortal Wkly Rep 1995;44:525-9.
25. Miller CL, Fletcher WB. Severity of notified whooping cough. BMJ 1995;1:117-9.
26. Herzig P, Hartmann C, Fischer D, Weil J, von Kries R, Giani G, et al. Pertussis complications in Germany: 3 years of hospital-based surveillance during the introduction of the acellular vaccine. Infection 1998;26:227-31.
27. Gil A, Oyaguez I, Carrasco P, Gonzalez A. Hospital admissions for pertussis in Spain, 1995-1998. Vaccine 2001;19:4791-4.
28. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004;23:246-52.
29. Juretzko P, Fabian-Marx T, Haastert B, Giani G, von Kries R, Wirsing von Konig CH. Pertussis in Germany: regional differences in management and vaccination status of hospitalized cases. Epidemiol Infect 2001;127:63-71.
30. De Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA, Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000;6:348-57.
31. Wortis N, Strebel PM, Wharton M, Bardenheier B, Hardy IRB. Pertussis deaths: report of 23 cases in the United States, 1992-1993. Pediatrics 1996;97:607-12.
32. Mikelova LK, Halperin SA, Scheifele D, Smith B, Ford-Jones E, Vaudry W, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003;143:576-81.
33. Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med 2000;26:1512-4.
34. Pooboni S, Roberts N, Westrope C, Jenkins DR, Killer H, Pandya HC, et al. Extracorporeal life support in pertussis. Pediatr Pulmonol 2003;36:310-5.
35. Williams GD, Numa A, Sokol J, Tobias V, Duffy BJ. ECLS in pertussis: Does it have a role? Intensive Care Med 1998;24:1089-92.
36. Heininger U, Kleemann WJ, Cherry JD; Sudden Infant Death Syndrome Study Group. A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics 2004;114:e9-e15.
37. Fung KSC, Yeung WL, Wong TW, So KW, Cheng AFB. Pertussis: A re-emerging infection? J Infection 2004;48:145-8.
38. Mink CM, Cherry JD, Christenson P, Lewis K, Pineda E, Shlian D, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992;14:464-71.
39. Rosenthal S, Strebel P, Cassiday P, Sanden G, Brusuelas K, Wharton M. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 1995;171:1650-2.
40. Gilberg S, Njamkepo E, Du Chatelet IP, Partouche H, Gueirard P, Ghasarossian C, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002;186:415-8.
41. Schmitt-Grohé S, Cherry JD, Heininger U, Uberall MA, Pineda E, Stehr K. Pertussis in German adults. Clin Infect Dis 1995;21:860-6.
42. Strebel P, Nordin J, Edwards K, Hunt J, Besser J, Burns S, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001;183:1353-9.
43. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infections in adults with persistent cough. JAMA 1995;273:1044-6.
44. Birkebaek NH, Kristiansen M, Seefeldt T, Degn J, Moller A, Heron I, et al. Bordetella pertussis and chronic cough in adults. Clin Infect Dis 1999;29:1239-42.
45. Wirsing von Konig CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995;346:1326-9.
46. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
47. Gustafsson L, Hollander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
48. Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
49. Lievano FA, Reynolds MA, Waring AL, Ackelsberg J, Bisgard KM, Sanden GN, et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 2002;40:2801-5.
50. Qin X, Turgeon DK, Ingersoll BP, Monsaas PW, Lemoine CJ, Tsosie T, et al. Bordetella pertussis PCR: simultaneous targeting of signature sequences. Diagn Microbiol Infect Dis 2002;43:269-75.
51. Lingappa JR, Lawrence W, West-Keefe S, Gautom R, Cookson BT. Diagnosis of community-acquired pertussis infection: comparison of both culture and fluorescent-antibody assays with PCR detection using electrophoresis or dot blot hybridization. J Clin Microbiol 2002;40:2908-12.
52. Cherry JD, Xing DX, Newland P, Patel K, Heininger U, Corbel MJ. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis 2004;38:502-7.
53. Trollfors B, Lagergard T, Gunnarsson E, Taranger J. Determination of pertactin IgG antibodies for the diagnosis of pertussis. Clin Microbiol Infect 2003;9:585-9.
54. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004;38:591-4.
55. Teunis PF, van der Heijden OG, de Melker HE, Schellekens JF, Versteegh FG, Kretzschmar ME. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 2002;129:479-89.
56. Bass JW. Erythromycin for treatment and prevention of pertussis. Pediatr Infect Dis J 1986;5:154-7.
57. Langley JM, Halperin SA, Boucher FD, Smith B; Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC). Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004;114:e96-e101.
58. American Academy of Pediatrics. Pertussis. In Pickering LK, editor. Red book 2003. Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): The Academy; 2003. p. 472-86.
59. Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 1997;100:65-71.
60. National consensus conference on pertussis, Toronto, May 25-28, 2002. Can Commun Dis Rep 2003;29(Suppl 3):1-33.
61. Klein J. Clarithromycin and azithromycin. Pediatr Infect Dis J 1998;17:516-7.
62. Pichichero ME, Hoeger WJ, Casey JR. Azithromicin for the treatment of pertussis. Pediatr Infect Dis J 2003;22:847-9.
63. Bace A, Zrnic T, Begovac J, Kuzmanovic N, Culig J. Short-term treatment of pertussis with azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis 1999;18:296-8.
64. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001;20:1149-54.
65. Wilson KE, Cassiday PK, Popovic T, Sanden GN. Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. J Clin Microbiol 2002;40:2942-44.
66. Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999;354:2101-5.
67. Irwin RS, Madison JM. The diagnosis and treatment of cough. N Engl J Med 2000;343:1715-21.
68. Pillay V, Swingler G. Symptomatic treatment of the cough in whooping cough [Cochrane review]. In: Cochrane Library, Issue 2, 2004.
69. Granstrom M, Olinder-Nielsen AM, Holmblad P, Mark A, Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet 1991;38:1230-3.
70. Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, McIver J, et al. Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J 1999;18:505-11.
71. Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 2004;114:e264-e266.
72. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1-36.
73. Wheeler JG, Tran TC, North P, Beavers-May T, Schutze GE, Snow SL. Barriers to public health management of a pertussis outbreak in Arkansas. Arch Pediatr Adolesc Med 2004;158:146-52.
74. Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 1998;120:143-9.
75. Dodhia H, Crowcroft NS, Bramley JC, Miller E. UK guidelines for use of erythromycin chemoprophylaxis in persons exposed to pertussis. J Public Health Med 2002;24:200-6.